Overture Life, described as the global leader in automated IVF and the first company to achieve live births from both robotic fertilization and robotic egg freezing, has received CE Mark certification in Europe for its DaVitri platform, marking a significant step in DaVitri fertility automation and access to assisted reproduction. With this regulatory milestone, DaVitri is now the first automation device cleared for freezing unfertilized eggs in either the EU or the U.S., and the first freezing system to secure approval with a validated claim for post-thaw blastocyst development rates, reinforcing the company’s position in DaVitri fertility automation and automated in vitro fertilization (IVF) technology. The CE Mark provides Overture Life with the regulatory backing needed to commercialize DaVitri in continental Europe, as well as in the UK and Turkey, markets that recognize CE mark certification for medical devices in fertility automation.

Based in Madrid and Palo Alto, Overture Life has built its reputation as a pioneer in automated in vitro fertilization (IVF), having already achieved live births using both robotic fertilization and robotic egg freezing. The DaVitri system, a compact tabletop device, is designed to automate one of the most technically challenging steps in embryology: vitrification of unfertilized oocytes. By standardizing this process, DaVitri reduces operator variability, shortens training times, and ensures consistent, lab-verified embryo formation outcomes. 

“This is a signal that Europe understands the personal and demographic urgency of reproductive freedom," said Overture Life CEO Hans Gangeskar. “The EU has shown its willingness to make long-term public investments in fertility infrastructure and support new technologies, and we hope to see other jurisdictions follow the same path.”

Alongside DaVitri, the rest of Overture Life’s portfolio of automated and AI-enabled reproductive technologies continues to advance, signaling a broader strategy to modernize IVF and embryology workflows. The company reports that use of its ICSI. A robot led to the first two live births resulting from an automated fertilization device in 2023, while its AI+metabolomics-based m|z platform for non-invasive healthy embryo selection is now available through a CLIA (Clinical Laboratory Improvement Amendments)-certified laboratory in Texas, further integrating data-driven selection tools into fertility care. 

In outlining its broader mission, Overture Life says it integrates engineering, reproductive medicine, and regulatory-grade validation to modernize embryology lab procedures, with a particular focus on egg freezing and embryo handling to lower repeated cycles, increase throughput, and help reduce the overall cost of IVF. With research and development based in Spain and active U.S. operations, including a CLIA-licensed laboratory for non-invasive embryo selection, the company emphasizes that it combines robotics, analytics, and clinical rigor to deliver tools that clinics and patients can trust.

Overture Life states that its DaVitri platform is designed to boost reliability and consistency in IVF, giving women and families worldwide more control over their fertility timelines, and notes that its backers include Overwater Ventures, GV, Khosla Ventures, Octopus Ventures and others committed to advancing the future of fertility through innovations such as DaVitri fertility automation.